Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Cut to "Hold" at Wall Street Zen

Key Points

• Bayer Aktiengesellschaft has been downgraded from a "buy" rating to a "hold" rating by Wall Street Zen, as reported in a recent research note.
• Despite the downgrade, Bayer has received several upgrades from other analysts, with Goldman Sachs and Kepler Capital Markets both raising their ratings to "strong buy" and "buy," respectively.
• For the latest quarter, Bayer reported earnings of $0.65 EPS on revenues of $15.27 billion, surpassing analyst expectations.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) was downgraded by equities researchers at Wall Street Zen from a "buy" rating to a "hold" rating in a research note issued to investors on Saturday.

BAYRY has been the topic of a number of other reports. The Goldman Sachs Group raised shares of Bayer Aktiengesellschaft from a "hold" rating to a "strong-buy" rating in a research report on Thursday, June 5th. Kepler Capital Markets upgraded Bayer Aktiengesellschaft from a "hold" rating to a "buy" rating in a research note on Wednesday, June 11th. Finally, Hsbc Global Res raised shares of Bayer Aktiengesellschaft from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, June 11th. Two investment analysts have rated the stock with a hold rating, one has given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, Bayer Aktiengesellschaft presently has an average rating of "Buy".

Bayer Aktiengesellschaft Price Performance

Shares of BAYRY traded up $0.06 on Friday, reaching $8.56. The stock had a trading volume of 832,139 shares, compared to its average volume of 662,303. The firm has a 50-day moving average of $7.64 and a 200 day moving average of $6.56. The firm has a market capitalization of $33.64 billion, a PE ratio of -9.30 and a beta of 0.86. Bayer Aktiengesellschaft has a twelve month low of $4.79 and a twelve month high of $8.65. The company has a quick ratio of 0.79, a current ratio of 1.25 and a debt-to-equity ratio of 1.07.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The company reported $0.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.63 by $0.02. The business had revenue of $15.27 billion for the quarter, compared to the consensus estimate of $13.39 billion. Bayer Aktiengesellschaft had a positive return on equity of 13.94% and a negative net margin of 7.26%. Sell-side analysts expect that Bayer Aktiengesellschaft will post 1.31 EPS for the current year.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.